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ABSTRACT
The recent advances in radiation delivery can improve tumour control probability (TCP) and reduce treatment-related
toxicity. The use of intensity-modulated radiotherapy (IMRT) in particular can reduce normal tissue toxicity, an objective
in its own right, and can allow safe dose escalation in selected cases. Ideally, IMRT should be combined with image
guidance to verify the position of the target, since patients, target and organs at risk can move day to day. Daily image
guidance scans can be used to identify the position of normal tissue structures and potentially to compute the daily
delivered dose. Fundamentally, it is still the tolerance of the normal tissues that limits radiotherapy (RT) dose and
therefore tumour control. However, the dose–response relationships for both tumour and normal tissues are relatively
steep, meaning that small dose differences can translate into clinically relevant improvements. Differences exist between
individuals in the severity of toxicity experienced for a given dose of RT. Some of this difference may be the result of
differences between the planned dose and the accumulated dose (DA). However, some may be owing to intrinsic
differences in radiosensitivity of the normal tissues between individuals. This field has been developing rapidly, with the
demonstration of definite associations between genetic polymorphisms and variation in toxicity recently described. It
might be possible to identify more resistant patients who would be suitable for dose escalation, as well as more sensitive
patients for whom toxicity could be reduced or avoided. Daily differences in delivered dose have been investigated within
the VoxTox research programme, using the rectum as an example organ at risk. In patients with prostate cancer receiving
curative RT, considerable daily variation in rectal position and dose can be demonstrated, although the median position
matches the planning scan well. Overall, in 10 patients, the mean difference between planned and accumulated rectal
equivalent uniform doses was 22.7Gy (5%), and a dose reduction was seen in 7 of the 10 cases. If dose escalation was
performed to take rectal dose back to the planned level, this should increase the mean TCP (as biochemical progression-
free survival) by 5%. Combining radiogenomics with individual estimates of DA might identify almost half of patients
undergoing radical RT who might benefit from either dose escalation, suggesting improved tumour cure or reduced
toxicity or both.
Radiotherapy (RT) is the most effective non-surgical
treatment of cancer.1 It is needed in the care of 50% of
patients with cancer at some time in their illness, forms
a major part of the treatment plan for 40% of those who
are cured of their cancer and is primarily responsible for
cure in 16%. Of those patients who receive RT, around
60% are treated with curative intent,2 so that radical RT is
used in over 100,000 patients in the UK each year. The
lifetime risk for cancer for people born since 1960 is now
estimated to be over 50%,3 so that RT will be required for
a quarter of the population at some point.
In terms of overall costs, cancer consumes about 5% of
health spending, and of that, about 5% is committed to
RT.4 Thus, RT is not only a highly efﬁcacious treatment but
also a highly cost-effective one.1 RT is an essential priority
for the National Health Service to improve cancer survival
to levels equivalent to those in countries with the best
outcomes.5 Given the scale of use and value from RT, continuing
investment in developing technologies is appropriate.6 This is all
the more important as our population grows older, and cancers
are diagnosed earlier. Developments in RT will also make an
essential contribution to the Cancer Research UK vision of
curing 75% of patients with cancer in 20 years’ time.7
Intensity-modulated radiotherapy (IMRT) reduces dose-limiting
toxicity. In turn, this has allowed dose escalation to improve
local control and cure,8–15 so the issue of toxicity remains.
Ideally, IMRT should be combined with image guidance to verify
the position of the target. At its most interactive, image-guided
radiotherapy (IGRT) uses daily CT imaging, on the treatment
couch, to adjust the patient’s position prior to treatment and
to improve the accuracy of dose delivery.16 This provides an
opportunity to use CT imaging for additional development
work, including assessment of daily delivered (accumulated)
dose (DA).
Major developments can be expected in RT, as the result of
progress in numerous areas. One of these is the study of the
genomics of radiation toxicity (radiogenomics), in which the UK
is a leading contributor.17,18 Improvements in imaging for target
volume delineation, treatment planning, technical developments
in treatment delivery, developments in understanding of tumour
response and ways to modify it resulting from genomics and
imaging, molecular targeted RT, combination with pharmaceu-
tical agents both old and new and drugs to abrogate toxicity
represent some of the other areas of exciting research and de-
velopment, which offer potential to improve the therapeutic
ratio.19–21
This article reviews aspects of normal tissue toxicities considered
from the point of view of both biological variation in (normal
tissue) response and day-to-day variation in physical dose. The
variation in toxicity that may be owing to underlying biological
variation will be discussed. The calculation of accumulated dose,
(DA), by recalculating the daily delivered dose based on image
guidance scans will be addressed. Finally, the possibility of
combining predictive testing of normal tissue sensitivity with
estimates of DA will be discussed.
THE THERAPEUTIC RATIO
The success of RT in eradicating tumours depends on the total
radiation dose delivered accurately. For most tumours, the
higher the dose, the higher the chance of local tumour control
and cure. There is a steep dose–cure relationship, both in ex-
perimental animal systems and in males. The fact that dose–
response curves are steep is very important, since it indicates
that small dose differences will translate into clinically relevant
improvements. In most tumours, and animal systems, a 5%
increase in dose will typically achieve an increase in tumour
control in the range of 5–10%.22
However, there are limits to the RT dose that can be given safely,
which are imposed by the tolerance of the normal tissues sur-
rounding the tumour.23 As the dose is increased, so the in-
cidence and severity of normal tissue damage also rises, and,
when severe, normal tissue damage can produce signiﬁcant
morbidity that can be life threatening. Thus, selection of the
appropriate treatment is based on a balance between lowering
the dose to keep the incidence of severe normal tissue compli-
cations at an acceptably low level and raising the dose to increase
the probability of local control and cure. Since toxicity impacts
on quality of life and cancer survival rates are increasing, the
avoidance of toxicity is growing in importance.
This balance between tumour control and potential toxicity
deﬁnes the therapeutic window. This is often represented pic-
torially by classical sigmoid dose–response curves, and the size
or “width” of the therapeutic index is represented by the dis-
tance between the curves for tumour control probability (TCP)
and normal tissue complication probability (NTCP). In Figure 1,
the standard therapeutic ratio is shown. This can be widened by
adding strategies to sensitize the tumour, which shifts the TCP
curve to the left, or protecting the normal tissue, which shifts the
NTCP curve to the right.
In most circumstances, it is the “late-reacting” tissues that deﬁne
tolerance, with the speciﬁcs depending upon the site treated.
These toxicities typically do not improve over time and indeed
may worsen. The breast represents an excellent example, in
which modern RT techniques can improve outcome.24 However,
some accelerated dose-fractionation schedules also lead to
Figure 1. Sigmoid dose–response curves for tumour and normal
tissue. A risk of significant normal tissue damage of 5% may be
accepted in order to achieve a tumour control probability (TCP)
of 50%, as illustrated here. For some tissues, such as the spinal
cord, a 5% risk of late damage would be unacceptably high. The
TCP curve can be shifted to the left by sensitising the tumour,
for example with chemotherapy, although some agents may
also have an effect on the normal tissue curve too. The normal
tissue complication probability (NTCP) curve can be shifted to
the right, for example using intensity-modulated radiotherapy
and image guidance to spare more normal tissue from high
doses. Ideally, strategies can be combined in order to shift the
tumour control curve left and the normal tissue curve right. This
will achieve a large rise in TCP with a fall in NTCP.
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“acute” dose-limiting toxicity. One of the most dramatic is the
continuous hyperfractionated accelerated radiotherapy) sched-
ule for lung cancer, delivering 54Gy in 36 fractions over
12 days.25 This highly effective schedule made ‘acute tolerance’
relevant. The addition of chemotherapy to RT, such as in head
and neck cancer, also leads to acute toxicity that is close to dose
limiting. However, late effects in these patients are also relevant
in deﬁning the upper limit of dose, even though some toxicities
can be reduced by the use of IMRT.12 There is likely some
relationship between the severity of acute and late toxicities in
individual patients but not sufﬁcient to use acute response as
a predictor of late effects.23
The steepness of the dose–response curves
The steepness of the dose–response curve can be usefully described
using the parameter Gamma-50 (g50), which describes the per-
centage increase in tumour control for a 1% increase in dose, at the
50% TCP level (Figure 2). Thus, achieving a 5–10% improvement
in TCP for a 5% increase in dose equates to a g50 value of 1–2.
The g50 concept can also be applied to normal tissues, although
for many end points, the 50% NTCP level is rarely if ever
reached. Here, it is usual to ﬁnd g50 values in the range 2–5,
although some normal tissue dose–response curves may be
shallower.26,27 Salivary gland toxicity, in the form of xerostomia,
has a g50 of 1,
28 while the spinal cord has a higher g50 of the
order of 4.2,29 indicating that careful attention to small changes
in dose, at near-tolerance levels, are even more important.
It is not always possible to prove that small dose changes improve
outcomes.22,30,31 However, there is substantial evidence of dose
response in both tumours and normal tissues, which provides
proof-of-principle, and the value of small changes can be ro-
bustly inferred from these types of data. Indeed, it is important
to do just that in considering opportunities for technological
development. Small dose changes can be detected clinically, as
demonstrated in the three-arm randomised trial with two ex-
perimental arms design,32 used, for example, in the START A33
and CHHiP trials.34
The slope of the sigmoid NTCP curves reﬂects heterogeneity
between patients, which is considered to relate, at least in part,
to normal genetic variation (that is, normal polymorphisms
rather than rare deleterious mutations). In contrast to clinical
ﬁndings, small animal experimental results show a steep dose–
response curve. The steepness reﬂects lack of genetic variation
between the inbred animals, highlighting a limitation of small
animal data when studying normal tissue toxicities in humans.
BIOLOGICAL DETERMINANTS OF
RADIOTHERAPY TOXICITY
In a given treatment setting, different patients experience dif-
ferent severities of toxicity. Some of this variation is the result of
differences in anatomy, of both the tumour target and sur-
rounding normal tissues, leading to variation in the doses de-
livered to the normal tissues. A component of this dose variation
results from day-to-day differences in position during the course
of treatment. Factors involved include variation in patient po-
sitioning, internal organ movement or progressive weight loss
during the treatment course. Positional variation can be im-
proved by the use of IGRT.
Where the dose variation is minimized, additional variation is
seen that is considered to reﬂect differences in underlying tissue
radiosensitivity, and which, in turn, may have a genetic basis.27,35
Clinical evidence suggests that as much as 80% of variation in
normal tissue response or toxicity may be owing to such bi-
ological variation.35,36 Investigation of this genetic aspect requires
the best possible knowledge and control of dose.27,37
The importance of toxicity to both patients and society is in-
creasing, as cure rates rise because of earlier cancer detection and
more effective treatment. The ﬁnancial cost of managing late
effects of cancer treatment in survivors is high. Reduction of
toxicity in cancer survivors will enhance the quality of life and
reduce the social and population burden from morbidity. Re-
ducing toxicity will also allow development of protocols for both
dose escalation and combination with conventional chemo-
therapy and newer molecular-targeted agents.
As well as identifying patients with increased normal tissue ra-
diosensitivity, it is also vital to identify patients with more
radioresistant tissues. This group of patients could in principle
be dose escalated to increase local control and cure, without
increasing their risk of toxicity.
Early descriptions of variation in individual normal
tissue response
The sigmoid dose–response curve represents a cumulative fre-
quency distribution, which is a transformation of a bell-shaped
Figure 2. Diagram to illustrate the concept of the parameter g-50,
that is, the percentage increase in tumour control (or alternatively
in normal tissue complication probability) for a 1% increase in
dose at the 50% effect level. TCP, tumour control probability.
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differential frequency distribution graph. Holthusen38 published
the ﬁrst formal description of this shape of dose response for
normal tissue in 1936 (Figure 3), and his work is a seminal study
in radiation oncology. However, the general notion of variation in
normal tissue response between individuals treated with the same
dose predates this. In the very earliest days of RT, at the beginning
of the 20th century, dose was typically prescribed as the “Ery-
thema Dose”, deﬁned as the dose (or exposure, often represented
by the time for which the X-ray tube was operating) required to
produce erythema in 80% of the patients.39 This fascinating
“unit” of dose implicitly embodies the concept of individual
variation. This concept appears to have been lost, perhaps over-
shadowed by the introduction of objective physical measurement
of dose based on ionisation, together with the introduction of
megavoltage (MV) machines with skin-sparing beams.37
Individual variation with the classic bell-shaped frequency dis-
tribution was described again in the 1950s.40 Acute40 and late41
effects showed considerable variation, with an approximately
gaussian distribution for both types of reaction. However, the
seminal work deﬁning dose response, and quantifying both
acute and late normal tissue effects in clinical fractionation
experiments on skin over a 20-year period, was performed in
Gothenburg by Turesson et al.35,37,42–44
Several syndromes of extreme radiosensitivity are known and are
typically associated with single genetic mutations, many in DNA
damage response pathways, which render them sensitive. By
contrast, variation in non-syndromic patients is thought to be
polygenic, and the result of polymorphisms, that is normal var-
iation, rather than deleterious mutations. The distribution of
sensitivity can be represented by a theoretical gaussian distribu-
tion, with the syndromic patients shown as outliers (Figure 4).
The concept that individual variation in normal tissue response
might be exploitable for predictive testing to individualize RT
appeared in the late 1980s and early 1990s.43,44,48–50 An im-
portant step was the recognition that in addition to some
individuals having greater toxicity, some have less normal tissue
toxicity than average.35,43,50,51 This allows the possibility for dose
escalation in more resistant patients, as well as for altered
management in more sensitive individuals. Dividing patients
into three groups, with 10% most sensitive, 50% intermediate
and 40% more resistant, provides an opportunity to dose-
escalate a large number of patients. Using data for late skin
toxicity as an example, it might be possible to dose-escalate
the resistant 40% by 17–19%.23 Even using a value of one for
g50, these dose increases should achieve an improvement in
TCP of 17–19%. A theoretical link between intrinsic normal
tissue and tumour radiosensitivity might appear to complicate
this, but bigger gains are actually possible if they are
correlated.48,52
As well as putative genetic variation as a cause for differences in
toxicity between individuals, a number of potential modifying
and confounding factors exist,37,53 such as use of other treat-
ments (e.g. concurrent chemotherapy or surgery), medi-
cations,54 patient factors (e.g. age, smoking, comorbidities such
as diabetes or hypertension and diseases such as scleroderma),
dosimetric factors (radiation doses to normal tissues) or eth-
nicity, which need to be considered as co-variables when ana-
lysing genetic variation associated with RT toxicity.
Surgical outcomes are also important. For example, in breast RT,
a poor post-operative cosmesis is an important determinant of
outcome.24,55 Prospective data collection is essential, and data on
modifying/confounding factors are not always recorded well.
How large is the biological variation in normal
tissue response?
A useful method of allowing comparison between biological
variation and physical dose variation is to translate the range
of biological variation into a dose equivalent. Using this
Figure 3. Classic sigmoid and bell-shaped dose–response curves for clinical normal tissue toxicity, redrawn from Holthusen.38 In this
case, the end point was telangiectasia of the skin, and dose is measured in Ro¨ntgen (r): 100 r approximately equals 1Gy. The sigmoid
curve (left) represents a cumulative frequency distribution, whereas the bell-shaped curve (right), which has been created by
transforming it, represents a differential frequency distribution. Note that this is not a true gaussian distribution because it has
a finite range and is skewed. This is almost certainly a true representation of the biology, where at least extreme resistance to
radiation is not plausible.
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approach, Turesson estimated that moving from the mean to
either end of the bell-shaped distribution is equivalent to 620%
change in dose (Turesson, personal communication) (Figure 5).37
The variation of 620%, which applies to both acute and late skin
reactions, can be used to estimate the potential for dose escalation
in resistant patients or the size of dose reduction required, or its
equivalent, for sensitive patients.
A similar dose equivalent range (623%) has been observed
in vitro in large studies of ﬁbroblast cellular sensitivity in cells
taken from non-syndromic patients having RT.37,47
Early efforts at predictive testing
In the late 1980s and early 1990s, radiobiologists investigated
various approaches for measuring radiosensitivity to predict
a patient’s likelihood of developing RT toxicity.18,56 The main-
stay of these investigations was the clonogenic survival assay.
Most of the work was performed using ﬁbroblasts derived from
the skin. Several small studies each showed a correlation be-
tween cellular sensitivity and normal tissue response,49,57–59 but
this could not be replicated in larger studies.47 The lymphocyte
G2 assay played an important role in establishing an inherited
component to radiosensitivity (see below). A number of other
assays were also explored intensively, although without success
in this area,60 and several decades would have to pass before
molecular genetic techniques became available to examine the
underlying genomic variation.
The single exception appears to be the T-lymphocyte apoptosis
assay.61 Lymphocytes from 348 patients with a variety of cancers
who experienced severe late RT reactions exhibited an impaired
apoptotic response after 8Gy in vitro irradiation.61 There was no
relationship with acute reactions. There was also a reduced in-
cidence of late toxicities in patients whose lymphocytes showed
the greatest apoptotic response. The area under the receiver–
operator characteristic curve for grade 3 late toxicity (which
occurred in 8% of patients) was 0.92. The positive predictive
value for grade 3 toxicity was 20%, and the negative predictive
value was 98.5%. These results indicate considerable potential of
the assay. This is undergoing further evaluation at present,62 and
if its effectiveness is conﬁrmed may revolutionize our approach
to normal tissue radiosensitivity. However, at present, there is
still no method for assessing radiosensitivity that can be used on
a routine clinical basis.
Heritability of normal tissue sensitivity
It appears that radiosensitivity has a high heritability component,
possibly accounting for as much as 70% of the variation.63 This is
based on several studies that investigated lymphocyte radio-
sensitivity in patients with a range of reactions and in their
ﬁrst-degree relatives.64–68 The fact that heritability was dem-
onstrated added to the concept that underlying genetic vari-
ation could be responsible for individual variation in toxicity.
Clinical individualisation of radiotherapy based on
cellular radiosensitivity testing
During the era of clonogenic assays, there were important early
efforts to address individualisation in some patients with radiation
sensitivity syndromes. Patients with Fanconi anaemia (FA) had
been known for many years to have increased sensitivity to DNA-
damaging (clastogenic) agents, including cyclophosphamide and
X-rays,69–72 related to increased chromosomal fragility. Despite
increased DNA damage, there is evidence that cells from patients
with FA have some DNA damage repair capability.60,73
One group was sufﬁciently disappointed with their results from
bone marrow transplantation that they undertook clinical ra-
diation sensitivity testing of their patients with FA on skin
patches in vivo prior to the procedure.74 Although the testing
was on individual patients, the results were combined to develop
a standardized strategy of RT dose reduction, which likely did
contribute to an improvement in outcomes.72 This work appears
Figure 4. Stylized frequency distribution of normal cellular and tissue response shown on a relative scale. At the left, the sensitive end
of the spectrum, some patients are known to have extreme sensitivity in both cells and tissues, including those homozygous for ataxia
telangiectasia mutations. At least some of these patients (e.g. the patient whose cells were designated 180BR45,46) are also sensitive to
chemotherapy agents with a mode of action involving DNA damage. Here, the normal range has been represented by an approximate
gaussian distribution. Although this is not perfectly correct biologically, it can provide estimates for the standard deviation of the distribution.
Questions remain about how far the tail extends to the sensitive (left) side of the curve; to the right, it is also likely that the distribution is
truncated (Figure 3). The near gaussian shape is consistent with clinical data and also with cellular sensitivity data.37,47 It can reasonably be
assumed that the range extends either side of the modal value for 2.5–4 standard deviations37 (adapted from Burnett et al37).
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to be the ﬁrst attempt to individualize RT doses based on
a measurement of individual radiosensitivity, although in this
case sensitivity was measured in vivo and applied to all patients
with FA rather than individually. An enormous reduction in the
administered dose of cyclophosphamide was also made and was
clearly important in the modiﬁed schedule, so the exact con-
tribution of the RT individualisation cannot be inferred.
In 1985, a patient with ataxia telangiectasia (AT) was treated
with RT for medulloblastoma with a dose-reduced schedule,
based on in vitro testing of his lymphocyte radiosensitivity
compared with normal controls.75 Treatment was completed
successfully, which is an important result given that cells from
patients with ATare about three times as sensitive as normal cells
for a given dose. This supports the hypothesis that intrinsic
cellular radiosensitivity correlates with in vivo clinical normal
tissue response to RT. It supports the concept that measure-
ments of cellular sensitivity might be able to predict normal
tissue response and so permit individualisation of RT.
Predictive molecular biomarkers
A molecular biomarker, TGF-b1, has been investigated as a predictor
of radiation pneumonitis.76 This is a candidate molecule involved in
ﬁbrosis, although its exact role is not entirely resolved. However,
despite early reports of a correlation,76–78 not all studies have dem-
onstrated a relationship,79 and more work is certainly required.80
Candidate gene studies
Efforts to link speciﬁc variations in candidate genes, especially in
DNA damage response pathways, to variation in toxicity were
encouraged by the associations demonstrated for patients with
radiosensitivity syndromes. For example, the genetic defect in
a cell line (180BR) from a patient who developed severe che-
motoxicity followed by fatal radiation toxicity45 was identiﬁed as
affecting the function of ligase IV, a DNA damage response
gene.46 Efforts to look at gene expression proﬁles, again in DNA
double-strand break repair pathways, were also unsuccessful.81
Several studies did report associations between genetic variation
in candidate genes and RT toxicity.17,27,82–85 There was initial
excitement that, in a study of 41 patients, 7 alleles in 5 genes
appeared to provide a “signature” of sensitivity for the de-
velopment of subcutaneous ﬁbrosis.83 However, all the candidate
gene studies failed to validate.86–88 This may not be surprising,
given that cancer susceptibility genes have been found in ap-
parent “gene deserts”,89 which highlights that our understanding
of the biology of cancer and its treatment is superﬁcial at best.
The possibility of linking a genetic signature with variations in
physical dose has been suggested85 but still requires the genetic
signature to be developed.
Genome-wide association studies
The development of technology to perform genome-wide as-
sociation studies (GWASs) became available some years ago and
has made a major contribution to the understanding of cancer
risk.89 That technology has now been applied to radiogenomics.
Logistically, there are some key issues in studying radio-
genomics, including the need to wait for the radiation sensitivity
“phenotype” (i.e. toxicity) to develop, which may take several
years. It is also necessary to control for modifying/confounding
factors, as noted above, and to collect data prospectively using
validated toxicity scoring tools. Large numbers of patients (many
Figure 5. Frequency distribution of normalized peak erythema of the skin (acute reaction), with a near gaussian shape (redrawn
from37). Superimposed is the estimate of the variation in dose required to move an “average” patient from the mean of the
distribution to the sensitive or resistant ends (Turesson37). The variation of 620% can be used to estimate the potential for dose
escalation in resistant patients. It can also give an indication of the dose reduction required, or its equivalent achieved with, for
example, hyperfractionation, to avoid toxicity in more sensitive patients. A similar dose equivalent range (623%) has been observed
in large studies of fibroblast cellular sensitivity in cells taken from normal patients having radiotherapy.37,47
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thousands) are required for any GWAS, and this also applies to
radiogenomics.
The last few years have started to produce deﬁnitive evidence
that genetic variation is linked to toxicity.88 The ﬁrst GWAS
result to be reported was an association between a single-
nucleotide polymorphism and the development of erectile
dysfunction in African-American males after RT for prostate
cancer.90 Further associations are emerging,91,92 and more are
sure to follow,93 especially as a result of international collab-
oration, most notably based on the international Radio-
genomics Consortium (RGC)94 and the REQUITE project.95
The RAPPER study,18 to which many UK centres have con-
tributed patients, has made a major contribution to the RGC.
Much more work, and especially much larger cohorts of
patients, will be needed if we are to realize the holy grail of
predictive testing. Nevertheless, the recent progress suggests
that this will be achievable.
PHYSICAL DETERMINANTS OF TOXICITY
Present RT treatments are based on static models of the patient
anatomy and do not take into account variation in patient po-
sition or shape and location of mobile internal organs. Un-
certainty in the dose actually delivered to normal tissues is
recognized as a limitation in RT at the present time.96
Considering accumulated dose—DA
Methods to calculate DA, as opposed to the planned dose, will
provide a better understanding of dose–response relationships in
normal tissues and allow development of active monitoring of
delivered dose and predicted toxicity during the course of
treatment. In turn, this will provide the opportunity to alter the
treatment plan accordingly, and even small differences will be
clinically worthwhile. The better the normal anatomical struc-
tures can be visualized, the easier this process will be, particu-
larly since automated methods for contouring will be required.
Any improvement in imaging quality will be valuable, and in
due course there may be a role for online imaging using MR-
Cobalt and MR-Linac machines.
The discrepancy between expected and observed toxicity for DA
should represent the difference in radiation sensitivity between
individuals, hypothesized to result from underlying genetic
factors, as discussed above. Recruitment to the RAPPER study of
patients in whom DA has been calculated would add a valuable
cohort, where more of the individual variation should be at-
tributable to the underlying biology. This emphasizes the im-
portance of linking physics and biology and the need for an
interdisciplinary approach to this work.
Organs at risk—the rectum as an example of
a critical structure
The rectum provides an example of a critical normal tissue
structure, which in effect is dose limiting in RT for prostate
cancer. It is subject to day-to-day variation, which is discussed
here. There are also minute-to-minute changes that can occur
during a treatment fraction; these are harder to evaluate and
control.97 Many other normal tissue structures are also impor-
tant but require further work.
The rectum and prostate are mobile internal structures that can
move up to 2 cm in the anteroposterior direction relative to the
pelvis, from one day to the next.98 It has been known for some
time that rectal ﬁlling varies with time during treatment and
that this can have important consequences. For example, de
Crevoisier et al99 demonstrated that in patients receiving RT for
prostate cancer, the incidence of biochemical failure, a surrogate
for local failure, was signiﬁcantly higher amongst those who had
a dilated rectum (deﬁned as a maximum cross-sectional area of
$11.2 cm2) at the time of planning. The same effect has also
been described by other groups.100,101
It is thought, very rationally, that this effect relates to movement
of the rectum. A distended rectum can displace the prostate
anteriorly. If this happens at the time of the planning scan but
then resolves before treatment, the dose plan will underdose the
posterior part of the target. This effect also alters the dose re-
ceived by the rectum (Figure 6). Simple methods to control the
size of the rectum include emptying the rectum before treat-
ment,103 although this may not be straightforward in routine
practice. Dietary interventions, a potential simple approach,
have not been shown to alter the incidence and severity of
gastrointestinal side effects.98,104
Toxicity can be modelled to a ﬁrst approximation as a solid
structure using the Lyman–Kutcher–Burman model.105 Al-
though much of the existing dose–response data suggest that
high doses are predominant in determining the risk of toxicity,
there is also evidence of other subtle effects of dose. Analysis of
the RT01 trial showed that the number of dose–volume histo-
gram (DVH) points that were violated106 and the shape of the
dose distribution were correlated with outcome.107
Variation in rectal position
An indirect way of studying possible changes in dose is to con-
sider the position of the rectum during the course of the treat-
ment, in relation to the treatment isocentre (or equivalent). A
variety of studies have demonstrated rectal motion in patients
treated with RT for prostate cancer.108–115 These studies were
small and tended to rely on a limited number of images acquired
during treatment, simply because of the logistics of collecting and
contouring large numbers of scans.
Our VoxTox study has been set up to examine this in detail.116
VoxTox is an interdisciplinary research programme funded by
Cancer Research UK, which brings together oncology, physics,
engineering and mathematics.116 DA will be correlated with tox-
icity in 2000 participants with cancers of the prostate or head and
neck or tumours of the central nervous system in order to
quantify the contribution of physical dose variation to toxicity.
The basis of the imaging is the daily TomoTherapy® (Accuray,
Sunnyvale, CA) MV fan-beam CT image guidance scans, which
are performed on every patient every day.117
So far, scans from 10 patients treated to 74Gy in 37 fractions
(Figure 6) have been analysed, providing a total of 3900 slices; all
were contoured manually by a single operator (JES).102 As ex-
pected, manual contouring was time consuming, with an esti-
mated 12h required per patient. This demonstrates that large-scale
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use of this imaging is impossible without automated con-
touring. Intraobserver variability of contouring on MV scans
(conformity index, 0.83) was similar to that previously seen
for kilo voltage (kV) scans.118,119 With the 10 patients com-
bined, the median position of the (axial) centre of the rectum
was close to its position on the kV planning scan. This ﬁnd-
ing is interesting in that it endorses the idea that the plann-
ing scan provides an acceptable estimate of position for
a group of patients, for the purposes of RT planning, but it
also shows that there are differences for individuals who are
not accounted for.
Variation in rectal dose
Several studies have conﬁrmed differences between planned and
delivered doses to the rectum in prostate RT.112–114,120,121 Based
on weekly cone beam CT scans, analysis suggests that the ma-
jority of patients (60%121 to 75%112) have worse rectal DVHs
than shown on the treatment plan. Hatton et al121 showed that
in 12 patients with prostate cancer, the average V40Gy for the
rectum was worse in all 12 and the V70Gy was worse in 9.
These studies have provided early data to support the notion
that DA is different from planned dose to the rectum in some
patients. A major impediment to further progress is the need for
an automated system to contour the rectum, or at an even more
sophisticated level, to track the voxels of the rectum from day to
day, both to calculate DA in a timely fashion and to do so for
a signiﬁcant number of patients.
Using the manual contours for the 10 patients mentioned above,
the daily rectal dose to produce DA was recalculated.
122 The
mean difference in equivalent uniform dose (EUD) was22.7 Gy
(5%) (median, 22.7 Gy), the minus sign indicating a reduction
in rectal dose. This represents a 5% mean dose reduction
compared with the planned dose. A reduction in EUD was
seen in 7 of the 10 patients. The largest dose reduction seen
was 210.2Gy (217%). Using D50% of the rectum, the mean
dose difference was 23.3 Gy, or 28% (median, 22.0 Gy, 26%),
while the largest difference seen was 217 Gy (238%).
Using our data, if dose escalation was undertaken in the seven
patients in whom the rectal EUD DA was less than the planned
dose, with doses increased up to the mean EUD, this would
allow a mean dose increase of just over 5Gy. This represents
7.4% of 74Gy and gives an estimate of the increase in TCP
(represented by biochemical progression-free survival) of 5.2%,
with some patients having a higher probability and some less
(maximum, 9.9%; minimum, 1.8%). Although this relates only
to our 10-patient cohort, it illustrates the principle of using DA
to reﬁne the individualisation of RT.
This DVH approach to analysis of DA has the advantage of
producing quantitative data that can be compared with the
equivalent planning data. However, it gives no spatial in-
formation about dose distribution; this is vital if links be-
tween physical dose difference and toxicity are to be
uncovered. The summing of DVHs from different fractions
can give misleading results, since the positions of the high
dose region will vary from fraction to fraction, and the lack of
spatial information means that potentially no tissue actually
receives the highest dose shown in the accumulated DVH.
Therefore, we have used algorithms based on those described
by Murray et al123 and Buettner et al106 to produce accu-
mulated rectal dose–surface maps (DSMs) for the 10 patients.
These show that, despite a median difference in dose (DA
minus planned dose) of only 20.06 Gy at the pixel level, the
range of dose differences was between 217.5Gy and 120.1Gy.
These differences affected areas of the rectal surface away from
the prostate, the region where set-up is veriﬁed, and are con-
sistent with data from cone beam imaging in three patients.123
DSMs for 2 of the 10 patients in our study are shown in
Figure 7.
Figure 6. Axial slices at the same level from two patients to illustrate differences in mean position at treatment compared with that
at planning. (a) Loaded rectum on kilo voltage (kV) scan from patient whose rectal position during treatment was 9.6mm more
posterior than at planning. (b) Empty rectum on Day 1 mega voltage (MV) scan from same patient as (a). (c) Empty rectum on kV
scan from patient with rectal position during treatment was 3.2mm more anterior than at planning. (d) Loaded rectum on Day
35 MV scan from same patient as (c). Reproduced from Scaife et al102 with permission from the British Institute of Radiology.
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COMBINING NORMAL TISSUE SENSITIVITY AND
ACCUMULATED DOSE (DA) DATA FOR
RADIOTHERAPY INDIVIDUALISATION
Considering the mean of our DSM data as an estimate of the
population mean, then 4 of the 10 patients had rectal dose
reductions greater than this. Coincidentally, one approach to
radiosensitivity testing might identify 40% of patients as
having more resistant normal tissue. Combining the two
approaches might identify 16% of patients (i.e. 1 in 6) who
might tolerate even greater dose escalation to the tumour
without increasing their NTCP. Table 1 illustrates the simple
approach of combining the biological sensitivity information
with the physical accumulated dose information to provide
individualisation from both strategies. In total, 48% (i.e. al-
most 1 in 2) might beneﬁt from the combination, with either
dose escalation, suggesting improved tumour cure or reduced
toxicity or both.
For radiosensitive patients, the initial assumption might be to
manage all 10% differently. However, if the strategy was to dose
reduce and then follow RT with some additional treatment,
potentially those with lower DA could receive standard RT. In
principle, DA could be assessed halfway through the course. If
deteriorating, hyperfractionation could be introduced to abro-
gate toxicity for suitable tumours (e.g. head and neck cancer),
since this has been shown to reduce toxicity.124 This strategy
might be unsatisfactory for prostate cancer if the a :b ratio is
conﬁrmed as a low ﬁgure; results from the CHHiP trial will be
important in clarifying this.34 Other therapeutic strategies might
also be possible.54 For those in categories to the lower right of
the table, the possibility of dose escalation is of interest, modest
in scale for 32% and higher for 16% of patients. Although the
escalation may be limited, small differences are worthwhile, as
noted above, and might be applicable to almost half the
population.
CONCLUSIONS
There is clear potential value in predicting an individual’s risk of
toxicity following RT. The optimal approach is likely to involve
both biological and physical data, and combining the two
presents synergistic opportunities.
Although there is considerable promise for biological predictive
tests, there are currently none that are clinically usable. All such
studies require large numbers of patients, with established toxicity
phenotypes, and the logistical challenges are considerable. GWASs
Figure 7. Dose–surface maps (DSMs) for Patient A, with the highest accumulated equivalent uniform dose (EUD) compared with
planned (15.3Gy) of the 10 patients and for Patient B with the lowest accumulated EUD compared with planned (210.2Gy). The
rectum was considered a cylinder, and daily delivered dose was sampled at a set of equally spaced points on each MV slice. The
cylinder was then “cut” at the point where a vertical line from the centroid of each outline crossed the posterior edge and
unfolded. The DSMs were summed over all the fractions, based on the superior–inferior positions of each image corrected for
the shifts applied at treatment. Results are shown as accumulated DSMs; planned DSMs are shown for comparison. The
difference DSM represents the difference for each pixel between accumulated and planned dose. Since the length of the MV CT
image set was less than that of the rectum, the difference DSM is shorter (shown in grey). Although Patient A had a median DA of
1.7Gy higher than planned, areas of the superior rectum received doses of up to 2.8Gy less than planned. Patient B had a median
DA of 20.8Gy compared with that planned; in this case, inferior and superior rectum received up to 13.9Gy more than planned.
A, anterior; L, left; P, posterior; R, right. Reproduced from Scaife et al122 with permission from the British Institute of Radiology.
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are revealing polymorphisms with deﬁnite links to toxicity risk,
and it is likely that the next few years will see an increasing
number of these.88,93,94 In addition, the GWAS approach is likely
to reveal much more about the underlying biology of radiation
normal tissue effects, which is an additional valuable goal.
There are challenges too in measuring physical determinants of RT
toxicity. Estimates of DA can already be made, using manual
contouring on image guidance scans. The challenge here is to be
able to automate the process in order to upscale the calculations,
to allow real-time estimates to be made so that alterations to
treatment become possible. The data presented represent only an
example of what might be achievable; signiﬁcant technical chal-
lenges remain before this could be introduced into routine care.
Different strategies for manipulating normal tissue dose and
sensitivity in order to achieve both reduced toxicity and
increased tumour control will be of considerable beneﬁt to
patients requiring RT. The development work for these two
strategies, as well as many others, is ongoing, and patients
should become the beneﬁciaries from the application of this
integrated multidisciplinary approach.
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